title: Estrogens and the diabetic kidney.
abstract: BACKGROUND
  Across all ages, the incidence and rate of progression of most nondiabetic renal diseases are markedly higher in men compared with age-matched women. These observations suggest that female sex may be renoprotective. In the setting of diabetes, however, this female protection against the development and progression of renal disease is diminished.
  
  
  OBJECTIVE
  This review aimed to summarize our current understanding of sex differences in the development and progression of diabetic renal disease, and of the contribution of sex hormones, particularly estrogens, to the pathophysiology of this disease. We also attempted to answer why female sex does not protect the diabetic kidney.
  
  
  METHODS
  Using terms such as gender, sex, diabetes, diabetic nephropathy, estrogens, and sex hormones, the PubMed database was searched for English-language articles; targeted searches were conducted using terms such as gender/sex differences in diabetic renal disease. No restrictions were imposed on publication dates.
  
  
  RESULTS
  Although the existing data regarding the sex differences in the incidence and progression of diabetic renal disease are inconclusive, the undisputed fact is that women with either type 1 or type 2 diabetes mellitus exhibit a much higher incidence of renal disease compared with nondiabetic women. It is conceivable that the loss of female sex as a renoprotective factor in diabetes may be related to the abnormal regulation of sex hormone concentrations. Both clinical and experimental data suggest that diabetes may be associated with an imbalance in estradiol concentrations. Supplementation with 17beta-estradiol or administration of selective estrogen receptor modulators reduces the incidence of diabetes and attenuates the progression of diabetic renal disease.
  
  
  CONCLUSIONS
  Serum concentrations of ovarian hormones may provide a new means for predicting future risk of renal complications in diabetes. Exogenous steroid hormones may be an effective treatment for attenuating the progression of diabetic nephropathy.
authors.affiliation: Department of Medicine, Georgetown University Medical Center, Washington, DC 20057, USA. cm255@georgetown.edu
authors.forename: Christine
authors.initials: C
authors.lastname: Maric
authors.forename: Shannon
authors.initials: S
authors.lastname: Sullivan
mesh_terms: D003922:Diabetes Mellitus, Type 1 / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology; D003928:Diabetic Nephropathies / Q000097:blood / Q000453:epidemiology / Q000503:physiopathology*; D018450:Disease Progression; D004967:Estrogens / Q000502:physiology*; D005260:Female; D006801:Humans; D015994:Incidence; D007333:Insulin Resistance / Q000502:physiology; D007668:Kidney / Q000503:physiopathology*; D008297:Male; D008593:Menopause / Q000502:physiology; D017698:Postmenopause / Q000502:physiology; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology; D012737:Sex Factors
chemical_list: D004967:Estrogens; D020845:Selective Estrogen Receptor Modulators